PT  - JOURNAL ARTICLE
AU  - TAICHI ISOBE
AU  - KEITA UCHINO
AU  - CHINATSU MAKIYAMA
AU  - HIROSHI ARIYAMA
AU  - SHUJI ARITA
AU  - SHINGO TAMURA
AU  - MASATO KOMODA
AU  - HITOSHI KUSABA
AU  - TSUYOSHI SHIRAKAWA
AU  - TAITO ESAKI
AU  - KENJI MITSUGI
AU  - SHIGEO TAKAISHI
AU  - KOICHI AKASHI
AU  - EISHI BABA
TI  - Analysis of Adverse Events of Bevacizumab-containing Systemic Chemotherapy for Metastatic Colorectal Cancer in Japan
DP  - 2014 Apr 01
TA  - Anticancer Research
PG  - 2035--2040
VI  - 34
IP  - 4
4099  - http://ar.iiarjournals.org/content/34/4/2035.short
4100  - http://ar.iiarjournals.org/content/34/4/2035.full
SO  - Anticancer Res2014 Apr 01; 34
AB  - Background: Bevacizumab (BV) is widely used in chemotherapy for metastatic colorectal cancer (mCRC). Although specific adverse events have been observed, their risk factors have not been clarified. Patients and Methods: 178 mCRC patients who underwent chemotherapy were retrospectively examined and correlations between possible risk factors and adverse events were analyzed. Results: 87 out of 178 patients were treated with BV-containing chemotherapy. Possible risk factors for BV-related adverse events were: remaining primary tumor, current bleeding, history of arterial thromboembolism (ATE), hypertension, and proteinuria, and these were observed in 22%, 2%, 7%, 16%, and 8% of patients, respectively. Patients with hypertension prior to chemotherapy developed significantly worse hypertension (p=0.018). Gastrointestinal bleeding occurred in 3 out of 18 patients with residual primary tumor (16.7%) and 6 out of 63 patients with no primary tumor (8.7%) (p=0.385). Conclusion: Pre-existing hypertension appears to be a risk factor for BV-related deterioration of hypertension.